Revenue +24%, margins compressed; Inovance approval pending
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q1 margin 70 bps below 11% guidance. PAT growth claimed +24% using normalized priors, but actual delivery is +2.1% YoY.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue growth (+24% YoY) and large order book (₹1.3+ Cr new wins, seating/lighting/sunroof entry) offset by margin compression (10.3% vs 11% guidance, PAT growth only 2.1% despite revenue jump). Key risk: Inovance JV China regulatory approval timeline uncertain; new segment (seating, sunroof) profitability unproven.
₹5557 Cr
Revenue · +23.8% YoY₹315.5 Cr
Reported PAT · +2.1% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue 26% YoY robust growth
OVERSTATEDDelivered 23.8% YoY (excluding prior period income normalization used by mgmt)
PAT grew 24% to ₹296 Cr vs prior ₹239 Cr (normalized)
MISSDelivered ₹315.5 Cr with actual YoY growth 2.1% (margin compression offset volume)
EBITDA margin 10.3%, confident in 11% ±50 bps guidance
METQ1 delivered 10.3% OPM, 70 bps below 11% midpoint; below guidance
Strong order pipeline, multiple new wins this quarter
METLighting ₹450 Cr, seating ₹390 Cr, sunroof ₹130+₹40 Cr, global 4W OEM entry confirmed
Green mobility 78% YoY growth, becoming scale business
METDelivered ₹542 Cr (+78%), now 10% of revenues; profitability journey early-stage per mgmt
Earnings quality
What changed since the last call
Seating entry: greenfield plant ₹320 Cr
New4-wheel passenger seating announced Q1; Board-approved Chhatrapati facility (Sambhajinagar), ops Q2 FY28, anchor customer secured. Highest kit-value in group. No prior commitment; new strategic pivot.
Margin guidance: unchanged at 11% ±50 bps
NeutralPrior guidance 11% ±50 bps maintained with 'bias to higher end.' Q1 delivered 10.3% (below), but mgmt reaffirms annual target unchanged despite commodity pressure and new low-margin business.
Inovance JV: regulatory delay introduced
DowngradePress Note 3 approval received (INR) but China host-country approval required. Recent China regulatory tightening noted. Timeline shifted from prior explicit SOP timing to 'hopefully next quarter clarity.' Capex proceeding; business continuity assured.
Export momentum: +60% this quarter
UpgradeQ1 FY26 ₹141 Cr → Q1 FY27 ₹228 Cr. New ₹390 Cr seating export orders (3 customers, 2-year cycle). Switches/labs also added. Mgmt now aspires to 2-3x absolute growth, up from prior vague commentary.
The Q&A
Analysts pressed on margin recovery timeline (monthly pricing from customers just started), seating competitive entry after 4-year JV effort, Inovance China risk, and whether PAT growth reflects operating leverage. Management held on guidance confidence and order book strength but conceded margin recovery 'expected from Q2' (hedging near-term).
Seating market entry, capex, ramp — Chandramouli Muthiah, Goldman Sachs
PartialHighly competitive, cannot share vehicle details (launches confidential). Kit value ₹30-40K per car, growing. ₹320 Cr capex for new facility. Facility end FY27 ops, incremental growth H2 via multiple plant ramps (mix of new business and capex for existing).
Inovance JV regulatory & SOP timeline — Chandramouli Muthiah, Goldman Sachs
PartialNo holdup currently. Plant construction on schedule. Both partners aligned on uninterrupted supplies. China regulatory review ongoing; partnership exploring localization path. Early days, clarity expected next quarter.
Green mobility profitability journey — Chandramouli Muthiah, Goldman Sachs
AnsweredCarved out separately to show visibility. Some businesses above corporate profitability; some new (lower). Target: by third full production year, achieve target profitability. Individual business journey varies.
Capex FY27 and FY28 — Chandramouli Muthiah, Goldman Sachs
AnsweredFY27 unchanged: ₹1,750 Cr. Total pipeline ₹3,800 Cr; ₹1,400 Cr spent to date; ₹2,400 Cr remaining over 18-24 months. Very comfortable cadence.
Margin recovery: pass-through timing — Raghunandan NL, Nuvama Research
PartialQ1 margin hit by 40 bps pass-through dilution (absolute cost basis, no markup). Wage hikes partially absorbed via efficiency/automation. Monthly price adjustments already started with some customers; quarterly adjustments with others. Commodity cycle resets per Q/H. Holding 11% ±50 guidance; recovery expected Q2+.
Exports growth and potential — Siddhartha Bera, Nomura Holdings
AnsweredQ1 FY26 ₹141 Cr → Q1 FY27 ₹228 Cr (50-60% growth). New ₹400+ Cr business in switches/labs + seating ₹390 Cr. Aspire to 2-3x absolute, depends on domestic growth maintaining 20-30% for export share to rise.
Inovance China regulatory risk mitigation — Rishi Vora, Kotak Securities
PartialNo restrictions on e-Axle imports as of now. In discussion with partner and China stakeholders on localization path. Confident solutions will be found. Early days; clarity next quarter. Aurangabad capex proceeding. DHT also on track.
Guidance
FY27 healthy growth outlook (not quantified)
MediumMgmt states 'continue to expect healthy growth' but no specific FY27 revenue target or CAGR given. Q1 delivered 24% but H2 base higher.
EBITDA 11% ±50 bps, bias to higher end
MediumUnchanged from prior. Q1 delivered 10.3% (70 bps miss). Mgmt expects commodity recovery, operational efficiency, and cost actions to bridge gap by FY27-end.
FY27 ₹1,750 Cr, ₹3,800 Cr total pipeline
HighMaintained. ₹1,400 Cr spent to date; ₹2,400 Cr remaining over 18-24 months, comfortably paced per mgmt.
Risks the call surfaced
Inovance JV regulatory
HighPress Note 3 (INR) approved but China host-country approval pending. Recent China regulatory tightening on technology partnerships noted. Delays could push e-Axle localization and product SOP timelines by quarters to years.
Margin compression
MediumQ1 impacted by commodity/gas inflation, wage increases across states. Pass-through dilution ~40 bps (absolute cost basis, no markup). Monthly pricing from 1-2 customers started; quarterly adjustments with others. Recovery timing uncertain.
New segment execution
MediumSeating: 4-wheel entry after 4-year JV effort with TACHI-S. Announced one anchor customer; targeting multi-customer scale (INR 30-40K kit value). Facility ₹320 Cr capex, ops Q2 FY28. Profitability unproven. Sunroof: facility end FY27, orders ₹500 Cr (two customers), ramp FY29. Execution risk on launch timing, cost control.
Customer concentration
MediumSeating export ₹390 Cr from 3 new customers (2-year cycle, realization FY29). Lighting ₹450 Cr from likely 1-2 OEMs. Sunroof ₹500 Cr order book from 2 new OEMs. New 4-wheel seating facility anchored by one customer. Large capex (₹320 Cr seating, ₹1,750 Cr FY27 total) gated on customer execution.
Management
Score 7/10. Transparent on cost headwinds (commodity 40 bps, wage inflation, pass-through mechanics). Specific on plant/order details. Used normalized priors for PAT comparison; downside narrative framing in export growth (aspires to 2-3x but depends on domestic, lowering implied clarity). Track record mixed. FY26 guidance 11% margins — Q1 FY27 delivered 10.3% (miss by 70 bps). New segment wins (seating, sunroof) just announced; long-cycle, unproven execution (Q2 FY28 for seating, FY29 for sunroof realization). Capex spending on track (₹1,400 Cr / ₹3,800 Cr pipeline).
1 · H2 FY27
Alloy wheel, 2-wheeler, lighting facility ramp-ups; seating facility capex
2 · Q2 FY28
Seating Chhatrapati plant ops start; export seating orders 2-year ramp begin
3 · FY29
Seating/sunroof/export orders full realization; Inovance clarity
Key risk: Inovance JV China regulatory approval timeline uncertain; new segment (seating, sunroof) profitability unproven.
Informational and educational content only. Not investment advice.